Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase iii studies

HIGHLIGHTS

• who: Ana-Maria Orbai from the Baltimore, MD, USA Division of, Johns Hopkins University School of Medicine have published the article: Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies, in the Journal: (JOURNAL) of 25/01/2022
• what: In this post-hoc analysis of pooled data from two phase III studies, treatment with tofacitinib resulted in lasting improvements in dactylitis, with minimal emergence of new dactylitis up to month 6, irrespective of dactylitis location.
• how: Both studies were conducted . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.